MedTrace Logo

Versartis International Trial in Adults With Long-Acting Growth Hormone

NCT02526420 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-07-26

No results posted yet for this study

Summary

A Phase 2, open-label dose-finding safety study of individualized monthly VRS-317 dosing for five months in adults with GHD.

Conditions

  • Adult Growth Hormone Deficiency

Interventions

DRUG

somavaratan

Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly

Sponsors & Collaborators

  • Premier Research Group plc

    collaborator UNKNOWN

  • Versartis Inc.

    lead INDUSTRY

Principal Investigators

  • Daniela Rogoff, MD, PhD · Versartis Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
23 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States
  • Australia
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02526420 on ClinicalTrials.gov